For instance, dinaciclib is an inhibitor of CDK1, CDK2, CDK5, and CDK9, and is active in a broad range of cancer cell lines originating from leukemia, melanoma, osteosarcoma and pancreatic cancer [[34], [35], [36], [37]]. Here, CDK2 is linked to osteosarcoma.